Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma

Area of Science:

• Oncology
• Cancer Research
• Biomarker Discovery

Background:

• Malignant peritoneal mesothelioma (MPeM) is an aggressive, incurable cancer linked to asbestos exposure.
• Current prognostic indicators for MPeM are limited, necessitating further research into predictive biomarkers.
• Understanding factors influencing MPeM prognosis is crucial for developing effective treatment strategies.

Purpose of the Study:

• To investigate the prognostic and predictive value of CD146 and survivin expression in malignant peritoneal mesothelioma (MPeM).
• To assess the correlation between CD146, survivin, and Ki-67 labeling index (Ki-67LI) in MPeM.
• To develop a nomogram for predicting overall survival (OS) in MPeM patients.

Main Methods:

• Immunohistochemistry was used to analyze CD146, survivin, and Ki-67 expression in 60 MPeM patient biopsies.
• Clinical data and follow-up information were collected to correlate biomarker expression with patient outcomes.
• Kaplan-Meier analysis, univariate and multivariate Cox regression, and nomogram construction were employed for survival analysis.

Main Results:

• CD146 was expressed in 31/60 and survivin in 34/60 MPeM specimens, both associated with Ki-67LI.
• Lower peritoneal cancer index (PCI), stage I, lower Ki-67LI, CD146, and survivin expression correlated with improved overall survival (OS).
• Multivariate analysis identified PCI, survivin, and chemotherapy (intraperitoneal and systemic) as independent prognostic factors for OS.

Conclusions:

• Lower expression of CD146 and survivin are significant positive prognostic markers in MPeM.
• Peritoneal cancer index (PCI) and specific chemotherapy regimens are also critical for predicting MPeM patient survival.
• The developed nomogram demonstrates good accuracy in predicting individual survival for MPeM patients.